StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Guidance upgrade, solid Q2 revenue trajectory, and major GMP-capacity milestone imply potential multiple re-rating. The open GMP facility and 125+ ModTail customers support higher long-term revenue visibility, while non-GAAP EBITDA improvements hint at improving profitability despite a current net loss.
What happened, with direct paths to the underlying reporting
Maravai LifeSciences reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with a net loss of $21.6 million and adjusted EBITDA of $8.7 million. Six-month revenue rose 24.4% to $117.3 million as TriLink and Cygnus grew, and management raised full-year 2026 guidance to $205–$215 million in revenue and $33–$35 million in adjusted EBITDA. The quarter also featured a GMP enzyme manufacturing facility opening and rapid ModTail adoption (125+ customers in one year), underpinning longer-term growth and potential margin expansion.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.